Greg Pyszczymuka - Apr 25, 2023 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)

Role: Chief Commerical Officer
Signature: /s/ Mark Oki as attorney-in-fact for Greg Pyszczymuka
Stock symbol: AYTU
Transactions as of: Apr 25, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/20/2023, 08:29 AM
Previous filing: Dec 21, 2022
Next filing: Jun 20, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AYTU	Common Shares	Options Exercise	$0	+833	+9.15%	$0.00	9.94K	Apr 25, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AYTU	Restricted Stock Units	Options Exercise	$0	-833	-33.32%	$0.00	1.67K	Apr 25, 2023	Common Shares	833		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023.
F2	Represents restricted stock units ("RSU"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.